1. Bhatti F, Strobel J, Tench C, Grech-Sollars M, Dineen RA, Sollmann N, Thust S. Apparent diffusion coefficient for genetic characterization of untreated adult gliomas: A meta-analysis stratified by methods. Neurooncol Adv 2025; 7: vdaf103.
  2. Budiansah I, Hardiansyah D, Riana A, Pawiro SA, Beer AJ, Glatting G. Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling. EJNMMI Physics 2025; 12: 26.
  3. Burian E, Sollmann N, Carballido-Gamio J. Editorial: Imaging-based methods for fracture risk assessment. Frontiers in Endocrinology 2025; 16: 3.
  4. Costa G, Yousefzadeh-Nowshahr E, Vasic V, Sun B, Nagel L, Wurzer A, Schilling F, Beer A, Weber W, Kossatz S, Glatting G. Digital Twins for Radiopharmaceutical Dosimetry: PBPK Modelling of [177Lu]Lu-rhPSMA-10.1 in a Preclinical mCRPC Model. Cancers 2025; 17: 3957
  5. Eberhardt N, Haggenmüller B. Sectional Imaging for Alveolar Echinococcosis. Visc Med 2025; 41: 7.
  6. Hardiansyah D, Patrianesha BB, Glatting G. Population pharmacokinetic modeling in radiopharmaceutical therapy: a review. Front Nucl Med 2025; Volume 5 - 2025
  7. Hardiansyah D, Riana A, Hänscheid H, Beer AJ, Lassmann M, Glatting G. Non-linear mixed-effects modelling and population-based model selection for 131I kinetics in benign thyroid disease. EJNMMI Physics 2025; 12: 37.
  8. Hardiansyah D, Riana A, Hänscheid H, Jabar JM, Beer AJ, Lassmann M, Glatting G. (131)I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling. EJNMMI Physics 2025; 12: 89.
  9. Hardiansyah D, Riana A, Hänscheid H, Jabar JM, Beer AJ, Lassmann M, Glatting G. Correction: (131)I therapy for benign thyroid disease: flexible single-time-point dosimetry using population-based model selection with non-linear mixed-effects modelling. EJNMMI Phys 2025; 12: 99.
  10. Hardiansyah D, Riana A, Yousefzadeh-nowshahr E, Beer A, Eiber M, Glatting G. Predicting Time-Integrated Activity of 177Lu Lu-PSMA-I&T in Kidneys Using Single-Time-Point 68Ga Ga-PSMA-HBED-CC PET/CT and Non-Linear Mixed-Effects Modeling. J Nucl Med 2025; 66: 3.
  11. Hardiansyah D, Yousefzadeh-nowshahr E, Adzim M, Hakim A, Kind F, Nemer U, Beer A, Meyer P, Glatting G, Mix M. Optimizing Kidney Time-Integrated Activity Estimates for 177Lu Lu-PSMA-617: Significance of Late SPECT/CT Acquisition. J Nucl Med 2025; 66: 3.
  12. Hardiansyah D, Yousefzadeh-Nowshahr E, Budiansah I, Nemer U, Riana A, Kind F, Beer AJ, Meyer PT, Glatting G, Mix M. Single-time-point tumor dosimetry using population-based model selection and nonlinear mixed-effects modeling in [177Lu]Lu-PSMA-617 therapy. Medical Physics 2025; 52: e70000
  13. Holzgreve A, Hellwig D, Barthel H, Beer AJ, Kobe C, Lapa C, Miederer M, Schwarzenböck S, Seifert R, Todica A, Herrmann K, Bengel FM, Schäfers M, Moka D, Luster M, Fendler WP. PET imaging utilization and trends in Germany: a comprehensive survey. EJNMMI 2025; 52: 4390-8.
  14. Ivashchenko OV, O'Doherty J, Hardiansyah D, Grassi E, Tran-Gia J, Heemskerk JWT, Hippeläinen E, Sandström M, Cremonesi M, Glatting G. Understanding time–activity curve and time-integrated activity variations in radiopharmaceutical therapy challenge: Experience and results. Med Phys 2025; 52: e70043.
  15. Kastratovic N, Kemmer M, Weinfurtner C, Schnell J, Neukötter K, Mayer-Steinacker R, Wittau M, Von Baer A, Schultheiss M, Stilgenbauer S, Beer A, Beer M, Döhner H, Vogele D, Gaidzik V. Sarcopenia in Patients with Bone and Soft Tissue Sarcomas: A Retrospective PET/CT-Based Cohort Study on Prevalence, Therapy Association, and Prognostic Relevance in a Subgroup with Longitudinal Imaging (n=92, Target n˜500). Oncology Research and Treatment 2025; 48: 1.
  16. Lisson CG, Götz M, Wolf D, Manoj S, Gallee L, Schmidt SA, Tausch E, Schneider C, Stilgenbauer S, Beer AJ, Beer M, Sollmann N, Lisson CS. Non-Hodgkin's lymphoma classification using 3D radiomics machine learning models for precision imaging in oncology. BMC Med Imaging 2025; 25(1): 435.
  17. Miksch J, Yousefzadeh-Nowshahr E, Hardiansyah D, Glatting G, Solbach C, Bolenz C, Zengerling F, Wiegel T, Beer M, Prasad V, Wester HJ, Beer AJ, Thaiss W. First clinical application of silicon-based [¹8F]siPSMA-14 in prostate cancer patients: A proof-of-concept study. Nuklearmedizin 2025; 64(5): 285-293
  18. Patrianesha BB, Peters SMB, Hardiansyah D, Ritawidya R, Privé BM, Nagarajah J, Konijnenberg MW, Glatting G. Single-time-point dosimetry using model selection and the Bayesian fitting method: A proof of concept. Physica Medica 2025; 129: 104868.
  19. Paukovitsch M, Fechner T, Felbel D, Moerike J, Rottbauer W, Klömpken S, Brunner H, Kloth C, Beer M, Sekuboyina A, Buckert D, Kirschke JS, Sollmann N. Opportunistic computed tomography (CT) assessment of osteoporosis in patients undergoing transcatheter aortic valve replacement (TAVR). Archives of Osteoporosis 2025; 20: 12.
  20. Pfister K, Huesmann S, Fink A, Friedl TWP, Mergel F, Schäffler HP, Hartkopf A, Lukac S, Veselinovic K, Mehmeti F, Campbell N, Pipinikas C, Deininger K, Beer A, Lorenz S, Beer M, Wiesmüller L, Janni W, Heublein S, Rack B. Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer. Int J Mol Sci 2025; 26(17): 8498.
  21. Prex V, Gilg A, Rasche V, Muench J, Beer A, Harms M, Loeffler J. Exploring EPI-X4 Derivatives: Stability, Biodistribution, and CAM Model Integration in CXCR4-Targeted Therapy Development using PET and MR Imaging. J Nucl Med 2025; 66: 2.
  22. Ramschütz C, Kloth C, Vogele D, Baum T, Rühling S, Beer M, Jansen JU, Schlager B, Wilke HJ, Kirschke JS, Sollmann N. Automated extraction of vertebral bone mineral density from imaging with various scan parameters: a cadaver study with correlation to quantitative computed tomography. Eur Spine J 2025; 34: 5034-44.
  23. Rühling S, Löffler MT, Kirschke JS, Sollmann N. Opportunistic Osteoporosis Screening at the Spine - Clinical Applications and Diagnostic Value. Osteologie 2025; 34: 266-74.
  24. Ryhiner M, Song Y, Hong J, Ferreira CVG, Rominger A, Kossatz S, Glatting G, Weber W, Shi K. A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitors. European Journal of Nuclear Medicine and Molecular Imaging 2025.
  25. Ryhiner M, Song YMH, Rominger A, Weber W, Kossatz S, Shi KY, Glatting G. Development and Validation of RPT-Specific Analytical Models for Cancer Cell Survival Prediction. J Nucl Med 2025; 66: 3.
  26. Seeling C, Dahlum S, Marienfeld R, Jan V, Rack B, Gerstenmaier U, Beer AJ, Mayer-Steinacker R, Thaiss W, Barth TFE, Seufferlein T, Gaisa NT, Stilgenbauer S, Janni W, Siebert R, Döhner H, Gaidzik VI. Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report. J Cancer Res Clin Oncol 2025; 151: 37
  27. Sollmann N, Hermsdörfer J, Kern J, Koerte IK, Zimmer C, Beer M, Reinsberger C, Müller HP, Schultz V. MACRO- AND MICROSTRUCTURAL BRAIN ALTERATIONS IN FEMALE SEMI-PROFESSIONAL SOCCER PLAYERS. Shock 2025; 64: S27-S8.
  28. Sollmann N, Ramschütz C, Glanz L, Bauer M, Jansen JU, Schlager B, Wilke HJ, Schmidt SA, Vogele D, Beer M, Kirschke JS. EX-VIVO AND IN-VIVO OPPORTUNISTIC ASSESSMENT OF VERTEBRAL BONE MINERAL DENSITY USING COMPUTED TOMOGRAPHY - ACCURACY AND CLINICAL IMPLICATIONS IN PATIENTS WITH VERTEBRAL FRACTURES. Shock 2025; 64: S28-S.
  29. Subangun RM, Hardiansyah D, Ibrahim RFI, Patrianesha BB, Hidayati NR, Beer AJ, Glatting G. Few-time-points time-integrated activity coefficients calculation using non-linear mixed-effects modeling: Proof of concept for [<sup>111</sup>In]In-DOTA-TATE in kidneys. Physica Medica: European Journal of Medical Physics 2025; 129.
  30. Trif N, Kloth C, Büttner SM, Egenrieder N, Wolf D, Schmidt SA, Vogele D, Sollmann N, Flack F, Peters L, Grüner B, Jungwirth B, Stenger S, Stamminger T, Beer M. Semi-quantitative software evaluation of COVID-19 CT examinations-correlation with clinical parameters. J Thorac Dis 2025; 17: 7571-84.
  31. Weber T, Smaxwil C, Hermann M, Lenschow C, Lorenz K, Steinmüller T, Trupka A, Negele T, Holzer K, Tzatzarakis E, Eilsberger F, Eberhardt N, Klinger C, Peth S. Results of (18)F-choline and (11)C-methionine positron emission tomography/computed tomography for the preoperative localization of hyperfunctional parathyroid glands in primary hyperparathyroidism. Surgery 2025; 180: 109056